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Background/Aims. Natriuretic peptides are associated with the cardiovascular disease risk under a range of diﬀerent circumstances.
However, less is known about whether this association is found also in young healthy subjects. Methods. 9 patients with dilated
cardiomyopathy and 26 healthy young subjects were studied. The myocardial blood ﬂow measurements were performed basally
and during adenosine infusion using PET. Results. S-proBNP concentrations were signiﬁcantly higher (2153 ± 1964 versus 28 ±
17ng/L, P = .000002) and adenosine-stimulated ﬂow lower (1.6±0.8v e r s u s3 .6±1.1mL·g−1·min−1, P = .00001) in patients with
dilated cardiomyopathy when compared to healthy subjects. S-proBNP concentration was inversely associated with adenosine
stimulated ﬂow in patients with dilated cardiomyopathy (r =− 0.75, P = .019) but not in healthy subjects (r =− 0.06, P = .84).
Conclusions. Natriuretic peptides are inversely associated with coronary vasoreactivity in patients with dilated cardiomyopathy
but not in healthy young subjects. Since reduced coronary vasoreactivity seems to be one of the earliest abnormalities in the
development of coronary artery disease, this might indicate that natriuretic peptides are not predictor of cardiovascular disease
risk in healthy young subjects.
1.Introduction
Natriuretic peptides are released in response to increased
ventricular wall stress [1] and myocardial ischemia [2].
Serum natriuretic peptide concentrations have been demon-
strated to correlate with systolic dysfunction, and NYHA
class and also have prognostic value [3]. Recently, it has
been found that these peptides may also be indicators of
cardiovascular events even in healthy, elderly individuals [4].
However, less is known whether this association is found also
in healthy young subjects.
Reduced coronary vasoreactivity seems to be one of the
earliest abnormalities in the development of coronary artery
disease. Although high costs and limited availability prevent
thewideruseofthemethod,PETenablesnoninvasive,quan-
titative, and accurate measurements of myocardial blood
ﬂow in humans [5]. Using PET, coronary vasoreactivity has
been found to be reduced in patients with coronary artery
disease, diabetes, hypertension, and dyslipidemias, and it
appears to correlate also with the risk factors of coronary
artery disease even in healthy young subjects [6].
The present PET study was designed to evaluate whether
natriuretic peptides are associated with coronary vasoreac-
tivity in patients with dilated cardiomyopathy and in healthy
young subjects. Myocardial blood ﬂow was determined
basally and during adenosine infusion using PET and
oxygen-15-labelled water ([15O]H2O).
2. Methods
2.1. Subjects. The characteristics of the patients with dilated
cardiomyopathy are summarized in Table 1. Nine subjects2 ISRN Cardiology
Table 1: Characteristics of the patients with dilated cardiomyopa-
thy [mean (SD)].
Gender (M:F) 7:2
Age (years) 58 (12)
Body mass index (kg/m2) 31.7 (5.0)
Blood pressure (mmHg) 114/73 (13/6)
NYHA class 2.3 (0.5)
LV ejection fraction (%) 32.0 (8.3)
LV mass (g) 315.5 (102.7)
Mitral regurgitation grade 2.0 (0.6)
QRS duration (ms) 138 (14)
Medications:
Diuretics 9/9
ACE-inhibitors 5/9
Angiotensin II blocker 4/9
ß-blockers 9/9
Digoxin 1/9
with symptomatic heart failure, idiopathic dilated cardiomy-
opathy (LV ejection fraction <45%, left bundle branch
block), and cardiac resynchronization therapy (CRT) were
included.Nopatienthadatrialﬁbrillationoratrioventricular
conduction disorders. All patients were clinically stable,
treated with CRT and optimized medical therapy, and did
not have evidence of decompensated heart failure at the time
of the study. Moreover, to study the association between
natriuretic peptides and coronary vasoreactivity in healthy
subjects, twenty-six asymptomatic nonsmoking men (age
34 ± 6y e a r s ,B M I2 6± 2kg/m 2, LV ejection fraction
67 ± 5 % )w e r ei n v e s t i g a t e d .T h e s es u b j e c t sw e r eh e a l t h ya s
judged by history and physical examination and were not
taking any medication. All healthy subjects were normoten-
sive and had normal glucose tolerance and lipid proﬁle.
All of the electrocardiograms, stress echocardiograms, and
echocardiographically determined LV masses, dimensions,
and functions were normal in studied healthy subjects.
The study was conducted according to the guidelines of
the Declaration of Helsinki, and the Ethics Committee of
the Turku University Central Hospital accepted the study
protocol. Each subject gave written informed consent.
2.2. Study Design. The study was performed at the Turku
PET Centre (Turku University Central Hospital, Turku,
Finland). In patients with dilated cardiomyopathy, the dose
ofß-blockadewasgraduallyreducedduring6daysbeforethe
PETstudies(toavoidreboundeﬀect),withdrawncompletely
2 days before the PET studies, and restarted again after the
PETstudies.Othercardiacmedicationwascontinuedduring
the PET studies. Pacemaker was switched oﬀ for 24 hours
before the PET studies. In all subjects, PET studies were
performed after an overnight fast. Additionally, the subjects
were instructed to avoid all caﬀeine-containing drinks and
foods for 12 hours before the PET studies.
Serum N-Terminal probrain natriuretic peptide (S-
proBNP) was determined immediately preceding the PET
studies. Myocardial perfusion was measured using 15O-water
and PET at rest and then after administration of adenosine.
The subjects’ electrocardiogram and heart rate were moni-
tored continuously during the studies. Blood pressure was
monitored throughout the procedures with an automatic
oscillometricbloodpressuremonitor(OMRONHEM-705C,
Omron Healthcare, Hamburg, Germany) during all PET
studies.
2.3. Measurement of Myocardial Perfusion. The positron
emitting tracer, [15O]water, was produced as previously
described [7]. The subjects were positioned supine in a
15-slice ECAT 931/08-12 tomograph (Siemens/CTI Inc.,
Knoxville, TN, USA). After the transmission scan, myocar-
dial perfusion was measured with an intravenous injection
of [15O] water (∼1.5GBq) at rest and 60 seconds after intra-
venous administration of adenosine (140µg/kg per minute).
Dynamic scan lasted for 6 minutes (6 ×5, 6 ×15, and 8 ×30
seconds). All data were corrected for dead time, radioactive
decay, and photon attenuation. Images were processed using
an iterative median root prior reconstruction algorithm [8].
2.4. Analysis and Calculation of Myocardial Blood Flow.
Regions of interest (ROI) were drawn in the lateral, anterior
and septal wall of the left ventricle in four representative
transaxial slices in each study as previously described [7].
The ROI outlined in the baseline images was copied to
the images obtained after adenosine administration. Values
of myocardial blood ﬂow (expressed in mL/gram of tissue
per minute) were calculated according to the previously
published method using the single-compartment model [9].
The arterial input function was obtained from the LV time
activity curve using a previously validated method [10], in
which corrections were made for the limited recovery of
the LV ROI and the spillover from the myocardial signals.
The average blood ﬂow of the lateral and anterior part of
the myocardium showed the lowest coeﬃcient of variation
and was used in further analysis. Coronary ﬂow reserve was
deﬁned as the ratio of the myocardial blood ﬂow during
adenosine infusion to ﬂow at baseline.
2.5. Assessment of Natriuretic Peptide. S-proBNP was mea-
sured using an electrochemiluminometric (ECLIA) method
(reagent kit: Roche, Mannheim, Germany; instrument:
Elecsys, Roche, Mannheim, Germany; analysed at Limbach
Laboratory, Germany).
2.6. Statistical Analysis. The results are expressed as mean
± standard deviation (SD). Student’s paired t-test was used
within the group comparisons and Student’s unpaired t-test
when two diﬀerent groups were compared. For correlation
analysis, Spearman’s correlation coeﬃcients were calculated.
P values less than .05 were interpreted as statistically signif-
icant. All statistical tests were performed with SAS statistical
analysis system (SAS Institute Inc., Gary, N.C., USA).
3. Results
3.1. Hemodynamic Measurements during PET. Heart rates,
blood pressures, and rate-pressure products during the PETISRN Cardiology 3
Table 2: Hemodynamic data during PET studies [mean (SD)].
Basal Adenosine
Heart rate (beats/min)
Patients with DCM 72 (12) 83 (14)∗
Healthy subjects 60 (9) 98 (10)∗
Systolic bp (mmHg)
Patients with DCM 115 (16) 116 (11)
Healthy subjects 122 (12) 124 (14)
Diastolic bp (mmHg)
Patients with DCM 71 (10) 73 (7)
Healthy subjects 71 (11) 70 (11)
RPP (mmHg/min)
Patients with DCM 8193 (1245) 9520 (1692)∗
Healthy subjects 7064 (1092) 12083 (1719)∗
DCM: dilated cardiomyopathy, bp: blood pressure, RPP: rate pressure
product (systolic bp × heart rate).
∗P<. 05 versus basal.
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Figure 1: Serum proBNP concentration (logarithm scale) was
inversely associated with adenosine stimulated ﬂow in patients with
dilated cardiomyopathy (black circle: r =− 0.75, P = .019) but not
in healthy subjects (open circle: r =− 0.06, P = .84).
study are presented in Table 2. Adenosine infusion induced a
signiﬁcant increase in heart rate and rate-pressure products.
3.2. Myocardial Blood Flow Values. Basal myocardial blood
ﬂow was not diﬀerent between patients with dilated car-
diomyopathy (0.78 ± 0.33mL·g−1·min−1) and healthy sub-
jects (0.81±0.21mL·g−1·min−1, NS). Adenosine stimulated
ﬂow was lower in patients with dilated cardiomyopathy
when compared to healthy subjects (1.6 ± 0.8v e r s u s3 .6 ±
1.1mL·g−1·min−1, P = .00001). Concordantly, coronary
ﬂow reserve was lower in patients with dilated cardiomy-
opathy when compared to healthy subjects (2.1 ± 0.7v e r s u s
3.6 ± 1.1, P = .000004).
3.3. Laboratory Parameters. Serum proBNP concentrations
were signiﬁcantly higher in patients with dilated cardiomy-
opathy when compared to healthy subjects (2153 ± 1964
versus 28 ± 17ng/L, P = .000002). LV ejection fraction
was inversely (r =− 0.69, P = .037) and NYHA class
positively correlated (r = 0.82, P = .0066) with serum
proBNP concentration in patients with dilated cardiomy-
opathy. Serum proBNP concentration was not signiﬁcantly
associated with the basal myocardial blood ﬂow in patients
with dilated cardiomyopathy and healthy subjects (NS).
Serum proBNP concentration was inversely associated with
adenosine stimulated ﬂow in patients with dilated car-
diomyopathy (r =− 0.75, P = .019) but not in healthy
subjects (r =− 0.06, P = .84) (Figure 1). Concordantly,
serum proBNP concentration was inversely associated with
coronary ﬂow reserve in patients with dilated cardiomyopa-
thy (r =− 0.73, P = .025) but not in healthy subjects
(NS).
4. Discussion
As expected, in the present study patients with dilated
cardiomyopathy and heart failure had increased serum
natriuretic peptide concentrations and reduced adenosine
stimulated myocardial blood ﬂow when compared to healthy
young subjects. However, we demonstrated that natriuretic
peptideconcentrationswereinverselyassociatedwithadeno-
sine stimulated ﬂow in patients with dilated cardiomyopathy
but not in healthy young subjects.
Patients with dilated cardiomyopathy have reduced
coronary vasoreactivity in the absence of ischemic heart
disease [11, 12]. The exact mechanism of reduced coronary
vasoreactivity in these patients is still unknown, but it
may relate to coronary endothelial and microcirculatory
dysfunction [13]. In the present study, the myocardial
blood ﬂow values in patients with dilated cardiomyopathy,
and healthy subjects agree with values reported by other
cardiovascular studies [11, 12]. As expected, patients with
dilated cardiomyopathy had reduced adenosine stimulated
myocardial blood ﬂow and coronary ﬂow reserve when
compared to healthy subjects.
Natriuretic peptides are released in response to increased
ventricular wall stress [1]. Serum natriuretic peptide concen-
trations have been demonstrated to correlate with systolic
dysfunction, NYHA class and also have prognostic value [3].
These associations between LV ejection fraction, symptoms,
and natriuretic peptides were also found in the present
study. Recently, a strong inverse correlation has been found
between serum proBNP concentration and coronary blood
ﬂow reserve by using Doppler ultrasound techniques [14].
In the present study, only a limited number of patients were
investigated. However, the study protocol was complicated
and laborious. Despite the limited study population, we
were able to demonstrate that natriuretic peptides are
inversely associated with coronary vasoreactivity in patients
with dilated cardiomyopathy. This indicate that vascular
dysfunction parallels with ventricular dysfunction.
In addition to heart failure serum, natriuretic peptides
are substantially increased during acute coronary syndromes
[15]. Thus, myocardial ischemia appears to be also a
key stimulus for these peptides. Moreover, it has been
speculated that natriuretic peptides might be even early
indicators of cardiovascular impairment [4]. Since coronary
dysfunction seems to be one of the earliest abnormalities in4 ISRN Cardiology
the development of coronary artery disease [16], increased
concentrations of natriuretic peptides may predict future
coronary artery disease in patients with dilated cardiomy-
opathy. This would indicate that especially patients with
dilated cardiomyopathy and increased natriuretic peptide
concentration need intensive treatment of cardiovascular
risk factors.
Recently, it has been found that natriuretic peptides may
be indicators of cardiovascular events even in healthy elderly
adults [4]. In the present study, healthy subjects were not
matched with the patients, since we wanted to speciﬁcally
investigate the association between natriuretic peptides and
coronary vasoreactivity in healthy young men who had no
risk factors such as obesity, smoking, diabetes, and dyslipi-
demia, which are known to further reduce coronary vascular
reactivity [6].Wedidnotﬁndanycorrelationbetweenserum
proBNP concentration and coronary vasoreactivity in these
subjects. This might indicate that natriuretic peptides are
not predictor of cardiovascular disease risk in healthy young
subjects.
5. Summary
The present study demonstrates that natriuretic peptides are
inversely associated with coronary vasoreactivity in patients
with dilated cardiomyopathy indicating that vascular dys-
function parallels with ventricular dysfunction. However,
we did not ﬁnd any correlation between serum proBNP
concentration and coronary vasoreactivity in healthy young
subjects. This might indicate that natriuretic peptides are
not predictor of cardiovascular disease risk in healthy young
subjects.
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